Company profile
Salubris Biotherapeutics Inc
Privately held: no public share price (Privately held US subsidiary founded 2016 by China-based Salubris Pharmaceuticals; funded by private rounds, no traded equity of its own. Parent: Salubris Pharmaceuticals Co., Ltd. (China). [resolved 2026-08-05 by resolve-null-is-public; source: https://www.biospace.com/salubris-biotherapeutics-announces-35-million-in-financing-and-provides-pipeline-progress-update]) · United States
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | CTLA-4 (antibody moiety) + IL-2Rβ (via IL-15/IL-15Rα fusion)Monoclonal antibody | Non-Small Cell Lung Cancer |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.